These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25397600)

  • 1. Building a more connected DSMB: better integrating ethics review and safety monitoring.
    Eckstein L
    Account Res; 2015; 22(2):81-105. PubMed ID: 25397600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Data and safety monitoring policy for National Institute of Allergy and Infectious Diseases clinical trials.
    Dixon DO; Weiss S; Cahill K; Fox L; Love J; McNamara J; Soto-Torres LE
    Clin Trials; 2011 Dec; 8(6):727-35. PubMed ID: 22024105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward a more comprehensive approach to protecting human subjects: the interface of data safety monitoring boards and institutional review boards in randomized clinical trials.
    Gordon VM; Sugarman J; Kass N
    IRB; 1998; 20(1):1-5. PubMed ID: 11655324
    [No Abstract]   [Full Text] [Related]  

  • 5. Monitoring participant safety in phase I and II interventional trials: options and controversies.
    Hibberd PL; Weiner DL
    J Investig Med; 2004 Nov; 52(7):446-52. PubMed ID: 15651260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical issues during the conduct of clinical trials.
    Silverman H
    Proc Am Thorac Soc; 2007 May; 4(2):180-4; discussion 184. PubMed ID: 17494728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Data safety monitoring boards: legal and ethical considerations for research accountability.
    Tereskerz PM
    Account Res; 2010 Jan; 17(1):30-50. PubMed ID: 20094929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioethics in the Oversight of Clinical Research: Institutional Review Boards and Data and Safety Monitoring Boards.
    Grady C
    Kennedy Inst Ethics J; 2019; 29(1):33-49. PubMed ID: 31080176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward protecting the safety of participants in clinical trials.
    Califf RM; Morse MA; Wittes J; Goodman SN; Nelson DK; DeMets DL; Iafrate RP; Sugarman J
    Control Clin Trials; 2003 Jun; 24(3):256-71. PubMed ID: 12757992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Data and safety monitoring boards: some enduring questions.
    Kowalski CJ; Hewett JL
    J Law Med Ethics; 2009; 37(3):496-506, 396-7. PubMed ID: 19723260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sharing interim trial results by the Data Safety Monitoring Board with those responsible for the trial's conduct and progress: a narrative review.
    Borg Debono V; Mbuagbaw L; Thabane L
    Trials; 2017 Mar; 18(1):120. PubMed ID: 28279205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Institutional review boards must conduct safety review.
    Maloney DM
    Hum Res Rep; 2005 Feb; 20(2):3. PubMed ID: 15839005
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety boards must report their conclusions to IRBs.
    Maloney DM
    Hum Res Rep; 1999 Oct; 14(10):3. PubMed ID: 11658061
    [No Abstract]   [Full Text] [Related]  

  • 15. Enhancing communication among data monitoring committees and institutional review boards.
    Taylor HA; Chaisson L; Sugarman J
    Clin Trials; 2008; 5(3):277-82. PubMed ID: 18559418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How confidential trial negotiations and agreements between the Food and Drug Administration and sponsors marginalize local institutional review boards, and what to do about it.
    Mann H
    Am J Bioeth; 2006; 6(3):22-4; discussion W49-50. PubMed ID: 16754442
    [No Abstract]   [Full Text] [Related]  

  • 17. Institutional review boards lack the moral legitimacy to reinterpret subpart D.
    Nelson RM
    Am J Bioeth; 2008 Apr; 8(4):37-9. PubMed ID: 18576252
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of the data safety and monitoring board in an international trial.
    NIMH Collaborative HIV/STD Prevention Trial
    AIDS; 2007 Apr; 21 Suppl 2():S99-102. PubMed ID: 17413269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extend the reach of institutional review boards first, then strengthen their depth.
    Spike J
    Am J Bioeth; 2008 Nov; 8(11):11-2. PubMed ID: 19061097
    [No Abstract]   [Full Text] [Related]  

  • 20. The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
    DeMets DL; Fleming TR; Whitley RJ; Childress JF; Ellenberg SS; Foulkes M; Mayer KH; O'Fallon J; Pollard RB; Rahal JJ
    Control Clin Trials; 1995 Dec; 16(6):408-21. PubMed ID: 8720018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.